Acute Myelogenous Leukemia (AML) Clinical Trials

A listing of Acute Myelogenous Leukemia (AML) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 12 clinical trials
Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

This phase II/III trial studies how well daunorubicin and cytarabine with or without uproleselan works in treating older adult patients with acute myeloid leukemia receiving intensive induction chemotherapy. Drugs used in chemotherapy, such as daunorubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by …

tyrosine
blast cells
cancer
methotrexate
cytarabine
  • 25 views
  • 14 Jun, 2021
  • 104 locations
Study to Improve OS in 18 to 60 Year-old Patients Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR

This open label, multicenter phase II/III study with multiple randomization phases at differents stages of AML treatment (induction, consolidation and HSCT where applicable) is designed to improve OS in younger (18 to 60 year-old) patients, with AML risk-adapted patient strategies. Within the intermediate risk AML group, optimal GvHD prophylaxis following …

idarubicin
blast cells
colony stimulating factor
filgrastim
venetoclax
  • 42 views
  • 25 Jan, 2021
  • 57 locations
Trial to Test the Effects of Adding 1 of 2 New Treatment Agents to Commonly Used Chemotherapy Combinations

The AML18 Trial will evaluate several relevant therapeutic questions in Acute Myeloid Leukaemia (AML), as defined by the WHO, and High Risk Myelodysplastic Syndrome. The trial is primarily

myelodysplastic syndrome with excess blasts-2
blast cells
myeloid leukemia
remission
vosaroxin
  • 381 views
  • 23 Jan, 2021
  • 83 locations
Decitabine Plus mBU/CY for High Risk Acute Leukemia With MRD Pre-HSCT

Allogeneic haematopoietic stem cell transplantation (allo-HSCT) remains one of the currently available curative therapies for acute leukemia (AL). Leukemia relapse is one of the mainly causes of transplant failure. We reported previously that patients with high-risk molecular biomarkers who still have detectable minimal residual disease(MRD) pre-HSCT were at very high …

busulfan
decitabine
minimal residual disease
cell transplantation
acute leukemia
  • 2 views
  • 24 Jan, 2021
  • 1 location
CAR-T CD19 for Acute Myelogenous Leukemia With t 8:21 and CD19 Expression

Chimeric antigen receptor (CAR-T) engineered T cells against the CD19 protein have been shown to be effective against acute lymphoma and lymphocytic leukemia and are approved by the US (FDA), European (EMA) and Health Basel. However, little information exists on using CD19CAR for treatment of recurrent or irresponsible to previous …

lymphoid leukemia
lymphoma
  • 0 views
  • 24 Jan, 2021
  • 1 location
CD123/CLL1 CAR-T Cells for R/R AML (STPHI_0001)

The treatment options for relapse/refractory B-cell acute myeloid leukemia(AML)are limited.CD123/CLL1 CAR-T Cells may have a permanent anti-tumor effect and became very attractive. This study

  • 5 views
  • 23 Jan, 2021
  • 1 location
Low Dose Decitabine + Modified BUCY Conditioning Regimen for High Risk Acute Myeloid Leukemia Undergoing Allo-HSCT

myeloablative conditioning regimen for high-risk patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (Allo-HSCT).

transplant conditioning
busulfan
myeloablative conditioning
decitabine
cytarabine
  • 29 views
  • 21 Jan, 2021
  • 1 location
Dec+Flu+Bu Conditioning Regimen for Elderly AML in CR Undergoing Allo-HSCT

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is reported to be able to improve the outcomes for elderly acute myeloid leukemia (AML) in complete remission (CR). At present, the

transplant conditioning
busulfan
myeloablative conditioning
decitabine
remission
  • 15 views
  • 28 Jan, 2021
  • 1 location
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML

after induction therapy in newly diagnosed acute myeloid leukemia (AML) is evaluated.

induction therapy
colony stimulating factor
flow cytometry
filgrastim
g-csf
  • 20 views
  • 22 Jan, 2021
  • 1 location
A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS CMML or AML

Study ASTX030-01 is designed to move efficiently from Phase 1 to Phase 3. Phase 1 consists of an open-label Dose Escalation Stage (Stage A) using multiple cohorts at escalating dose levels of oral cedazuridine and azacitidine (only one study drug will be escalated at a time) followed by a Dose …

azacitidine
chronic myelomonocytic leukemia
direct bilirubin
blast cells
bone marrow procedure
  • 0 views
  • 26 Jan, 2021
  • 3 locations